CBRE Groupの空売り状況は、投資家がCBRE Groupの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

CBRE Group (NYSE:CBRE) 株価情報, 空売り情報

CBRE Group

CBRE Group provides a wide range of real estate services to owners, occupants, and investors worldwide, including leasing, property and project management, and capital markets advisory. CBRE's investment management arm manages over $140 billion for clients across diverse public and private real estate strategies.

CBRE Group Inc

CBRE Global Real Estate Income Fund Common Shares of Beneficial Interest

CBRE Clarion Global Real Estate Income Fund

On Wednesday,&nbsp;GE HealthCare&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEHC#NASDAQ">GEHC</a>) reported first-quarter 2025 adjusted EPS of $1.01, which beat the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of 91 cents</a>. It was up from 90 cents a year ago.
The company reported sales of $4.78 billion, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/25/04/45105997/ge-healthcare-q1-earnings-beat-expectations-tariffs-to-impact-2025-profit-outlook" rel="noreferrer noopener">consensus of $4.66 billion</a>.
GE HealthCare updated 2025 full-year guidance to include the estimated impact of announced tariffs. It reaffirmed organic revenue growth of 2% to 3% year over year for 2025.
The company expects an adjusted EBIT margin of 14.2% to 14.4%, down from its prior guidance of 16.7% to 16.8%.
BofA Securities writes GE HealthCare&#8217;s strong Q1 and record 10% organic order growth understandably took a back seat to tariffs.
Analyst Craig Bijou writes, &#8220;The 2025 tariff impact was larger than expected, but GEHC appears to have moved quickly and aggressively to mitigate the impact, already offsetting more than 50% of the gross headwind. Notably, GEHC expects the 2026 tariff impact to be less than the 2025 because of ongoing and future mitigation efforts.&#8221;
The analyst writes that GE HealthCare expects the 2026 tariff impact to be less than 2025, implying an additional $300 million or more offsets, assuming a $800 million annualized tariff run rate.
It&#8217;s unclear which tariffs might apply to Pharmaceutical Diagnostics (PDx) products; the company hasn&#8217;t factored in any impact from them. However, many PDx products are likely made in Europe, which could help them avoid the highest tariffs. Additionally, PDx has strong pricing power, which means it may be able to pass any tariff-related costs on to customers.
<ul>
<li>BofA reiterates a Neutral rating, given tariff uncertainty, despite the strong start to 2025, and lowers the <a href="https://www.benzinga.com/quote/GEHC/analyst-ratings" target="_blank" rel="noreferrer noopener">price target from $97 to $82</a>.</li>
<li>Wells Fargo maintains a rating for GE HealthCare as Overweight, lowering the price target from $103 to $89.</li>
<li>Citigroup maintains a Buy rating on GE HealthCare, lowering the price target from $105 to $86.</li>
<li>Evercore ISI maintains a rating of Outperform for GE HealthCare, lowering the price target from $96 to $85.</li>
</ul>
Price Action: GEHC stock is down 3.18% at $68.09 at the last check Thursday
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/05/45143938/thomson-reuters-maintains-strong-fy25-outlook-highlights-innovation-ai-as-key-growth-drivers" target="_blank" rel="noreferrer noopener">Thomson Reuters Maintains Strong FY25 Outlook, Highlights Innovation, AI As Key Growth Drivers</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Earnings

News

Guidance

Health Care

Price Target

Analyst Ratings

Movers

Trading Ideas

General

GEHC

GE HealthCare's Strong Q1 Took Back Seat To Tariffs, Analyst Sees 2026 Tariff Impact Less Than 2025

Barrington Research analyst Gary Prestopino maintains Stoneridge (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRI#NYSE">SRI</a>) with a Outperform and maintains $16 price target.

Barrington Research Maintains Outperform on Stoneridge, Maintains $16 Price Target

<a href="https://www.reuters.com/business/world-at-work/jetblues-plan-domestic-partnership-faces-union-backlash-2025-05-01/" title="https://www.reuters.com/business/world-at-work/jetblues-plan-domestic-partnership-faces-union-backlash-2025-05-01/">https://www.reuters.com/business/world-at-work/jetblues-plan-domestic-partnership-faces-union-backlash-2025-05-01/</a>

Management

JBLU

'Jetblue's Plan For Domestic Partnership Faces Union Backlash' - Reuters Exclusive

BWS Financial analyst Hamed Khorsand maintains Shenandoah (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHEN#NASDAQ">SHEN</a>) with a Buy and maintains $26 price target.

SHEN

BWS Financial Maintains Buy on Shenandoah, Maintains $26 Price Target

Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) announced that&nbsp;CVS Health Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) CVS Caremark, a Pharmacy Benefit Manager (PBM), has decided that Wegovy&nbsp;(semaglutide) injection 2.4 mg will soon be the preferred&nbsp;GLP-1&nbsp;medicine on its largest commercial <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">template formularies</a>.
This change will take effect on July 1, 2025. 
&#8220;We believe in the unique benefits of Wegovy and the difference this medicine can make for patients seeking treatment,&#8221; said Dave Moore, executive vice president of U.S. Operations and president of Novo Nordisk Inc.
Independent of this formulary decision, Novo Nordisk will continue to <a target="_blank" href="https://www.prnewswire.com/news-releases/novo-nordisk-announces-that-cvs-caremark-the-countrys-largest-pbm-has-decided-wegovy-will-be-the-preferred-glp-1-medicine-covered-for-obesity-on-its-template-formularies-302443603.html" rel="noreferrer noopener">work</a> with CVS to identify additional ways to expand access to Wegovy&nbsp;for its customers.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/45019869/novo-nordisk-wins-legal-battle-to-curb-unsafe-knockoff-versions-of-ozempic-wegovy" rel="noreferrer noopener">Novo Nordisk Wins Legal Battle To Curb Unsafe Knockoff Versions Of Ozempic, Wegovy</a>
In February, the FDA confirmed that all doses of Wegovy were available. In March, Novo Nordisk launched NovoCare Pharmacy to provide direct-to-patient, convenient home shipments of all Wegovy dose strengths at a reduced cost of $499 per month for <a href="https://www.benzinga.com/25/03/44143391/novo-nordisk-boosts-wegovy-access-with-lower-pricing-and-home-delivery" target="_blank" rel="noreferrer noopener">self-paying patients</a>.
More recently, the Wegovy savings offer was updated, allowing eligible self-paying patients to get the $499-per-month price at their local pharmacy.
The FDA expanded the label in 2024 to include an indication for reduction of the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight.
On Tuesday, Novo Nordisk&nbsp;and&nbsp;Hims &amp; Hers Health, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) announced a&nbsp;<a target="_blank" href="https://www.benzinga.com/25/04/45074872/hims-hers-stock-surges-as-it-collaborates-with-novo-nordisk-to-sell-weight-loss-drug-wegovy-on-its-platform" rel="noreferrer noopener">long-term collaboration</a>.
The company said that at a single, unified price starting at $599 per month, individuals may be prescribed Wegovy. The offering is available this week on the Hims &amp; Hers platform.
This new offering builds on Hims &amp; Hers' existing suite of weight loss solutions and provides self-pay patients with access to all dose strengths of Wegovy in a high-quality pen.
Price Action: NVO stock is down 1.78% at $65.27 at the last check Thursday
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/05/45136276/mounjaro-maker-eli-lilly-clocks-45-jump-in-q1-revenue-cuts-2025-profit-outlook-but-not-due-to-tariffs" target="_blank" rel="noreferrer noopener">Mounjaro Maker Eli Lilly Clocks 45% Jump In Q1 Revenue, Cuts 2025 Profit Outlook But Not Due To Tariffs</a></li>
</ul>
Photo: Shutterstock

Biotech

Large Cap

Contracts

Hims & Hers Health, Inc. Class A Common Stock

HIMS

CVS Caremark To Place Novo Nordisk's Wegovy On Preferred Coverage For GLP-1 Weight Loss Treatment

<a href="https://truthsocial.com/@realDonaldTrump/posts/114433942825461076" title="https://truthsocial.com/@realDonaldTrump/posts/114433942825461076">https://truthsocial.com/@realDonaldTrump/posts/114433942825461076</a>

Macro Economic Events

Politics

Economics

Donald J. Trump Posts On Truth Social "I am pleased to announce that I will be nominating Mike Waltz to be the next United States Ambassador to the United Nations... In the interim, Secretary of State Marco Rubio will serve as National Security Advisor, while continuing his strong leadership at the State Department. ..."

Barrington Research analyst Michael Petusky maintains OPKO Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPK#NASDAQ">OPK</a>) with a Outperform and maintains $2.25 price target.

Barrington Research Maintains Outperform on OPKO Health, Maintains $2.25 Price Target

<a href="https://teamster.org/2025/05/pepsico-pittston-workers-ratify-contract-with-local-401/#:~:text=The%20new%20five%2Dyear%20agreement,resilience%20and%20tenacity%20during%20negotiations" title="https://teamster.org/2025/05/pepsico-pittston-workers-ratify-contract-with-local-401/#:~:text=The%20new%20five%2Dyear%20agreement,resilience%20and%20tenacity%20during%20negotiations">https://teamster.org/2025/05/pepsico-pittston-workers-ratify-contract-with-local-401/#:~:text=The%20new%20five%2Dyear%20agreement,resilience%20and%20tenacity%20during%20negotiations</a>.

'PepsiCo Pittston Workers Ratify Contract With Local 401' - Teamsters

Chevron Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>) and Exxon Mobil Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) are gearing up to report first-quarter<a href="https://www.benzinga.com/earnings"> earnings</a> on Friday morning &#8211; and let's just say neither has been lighting up the charts lately.
With both stocks stuck in the red this year and crude oil prices trading sideways, investors are wondering: is this just a detour, or are we watching a slow-motion stall?
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0501"><img loading="lazy" decoding="async" width="627" height="489" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/01125801/Screenshot-2025-05-01-at-10.18.06-PM.png" alt="" class="wp-image-897486" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/01125801/Screenshot-2025-05-01-at-10.18.06-PM.png 627w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/01125801/Screenshot-2025-05-01-at-10.18.06-PM-300x234.png 300w" sizes="(max-width: 627px) 100vw, 627px" /></a></figure>
<a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0501" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
Chevron enters the earnings ring bruised &#8211; down nearly 20% in just a month and down 7.46% year to date. Wall Street expects earnings per share of $2.18 on revenue of $48.09 billion. But the technicals are less than inspiring: CVX stock trades below its eight, 20, 50 and 200-day simple moving averages (SMAs), and at $135.77, it's flashing a series of bearish signals.
Moreover, the 50-day SMA has just crossed below the 200-day SMA, making the dreaded Death Cross &#8211; validating the overall bearish setup.
Read Also: <a href="https://www.benzinga.com/news/25/05/45138403/exxon-mobil-xom-stock-drops-11-in-april-amid-crude-oil-price-collapse">Exxon Mobil (XOM) Stock Drops 11% In April Amid Crude Oil Price Collapse</a>
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0501"><img loading="lazy" decoding="async" width="627" height="489" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/01125809/Screenshot-2025-05-01-at-10.18.22-PM.png" alt="" class="wp-image-897488" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/01125809/Screenshot-2025-05-01-at-10.18.22-PM.png 627w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/01125809/Screenshot-2025-05-01-at-10.18.22-PM-300x234.png 300w" sizes="(max-width: 627px) 100vw, 627px" /></a></figure>
<a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0501" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
Exxon Mobil isn't exactly doing cartwheels, either. Shares are down over 11% this month and 1.58% year to date. Analysts are penciling in EPS of $1.70 on a much beefier $86.09 billion in revenue. But just like its rival, XOM stock is trading below every major moving average &#8211; eight-day, 20-day, 50-day and 200-day &#8211; putting it squarely in the "strongly bearish" camp.
Both companies are facing earnings pressure due to crude oil volatility, questions about global demand, and green-energy headwinds in the backdrop. But one key difference? Exxon's revenue base is nearly double Chevron's for the quarter, meaning it has more room to absorb macro pressure &#8211; or disappoint spectacularly.
With both giants fighting technical gravity and no near-term catalyst in sight, Friday's earnings aren't just about profit &#8211; they're about direction. Can either name buck the trend and give investors a reason to come off the sidelines? Or will they both get drilled?
Either way, the market's about to find out which of Big Oil's two biggest names still has gas in the tank.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45106246/crude-reality-energy-sector-becomes-sp-500s-worst-performer-thanks-to-trumps-tariff-turmoil">Crude Reality: Energy Sector Becomes S&amp;P 500&#8217;s Worst Performer, Thanks To Trump&#8217;s Tariff Turmoil</a></li>
</ul>
Photo: Shutterstock

Technicals

Previews

Chevron Vs. Exxon: Oil Giants Limp Into Q1 Earnings With Engines Stalling

Wayfair Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/W#NYSE">W</a>) shares are trading higher on Thursday after <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/n45129675/wayfair-announces-first-quarter-2025-results-reports-further-share-capture-with-robust-profitabili" rel="noreferrer noopener">reporting first-quarter results.</a>
The company reported adjusted earnings per share of 10 cents, beating the street view of 20 cents loss. Quarterly sales of $2.73 billion (almost flat year over year) outpaced the analyst consensus estimate of $2.71 billion.
U.S. net revenue rose 1.6% year over year to $2.4 billion.
International net revenue fell 10.9% to $301 million. On a constant currency basis, international revenue declined 7.1%.
Also Read: <a target="_blank" href="http://benzinga.com/general/social-media/25/04/44747892/amazon-wayfair-pinterest-win-analyst-backing-due-to-tariff-pause-supply-chain-relief-discretionary-spend-recovery" rel="noreferrer noopener">Amazon, Wayfair, Pinterest Win Analyst Backing Due To Tariff Pause, Supply Chain Relief, Discretionary Spend Recovery</a>
The company said it recorded net charges of $23 million for the quarter that ended March 31, primarily due to $20 million tied to restructuring efforts and macroeconomic challenges in Germany and $3 million related to changes in sublease market conditions for a U.S. technology center.
Gross profit in the quarter under review increased to $837 million, higher than $819 million in the year-ago period.
As of March 31, active customers totaled 21.1 million, a decrease of 5.4% year over year. Orders delivered in the quarter were 9.1 million, a decrease of 5.2% year over year.
Average order value was&nbsp;$301&nbsp;in the first quarter, compared to&nbsp;$285&nbsp;in the first quarter of 2024.
Adjusted EBITDA in the quarter under review increased to $106 million, higher than $75 million a year ago.
Adjusted EBITDA Margin expanded to 3.9% from 2.7% a year ago.
Cash, cash equivalents and short-term investments totaled&nbsp;$1.4 billion&nbsp;and total liquidity was&nbsp;$1.8 billion, including availability under the company&#8217;s revolving credit facility.
&#8220;Tariffs are clearly top of mind for everyone — while there&#8217;s a lot of uncertainty in the broader economy, we have direct line of sight and strong conviction on what we need to do for both our customers and our suppliers,&#8221; said Niraj Shah, CEO, co-founder and co-chairman, Wayfair.
Price Action: Wayfair shares are trading higher by 2.65% to $31.10 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45137383/microsoft-rallies-after-crushing-q3-earnings-goldman-sachs-lifts-target-to-480" target="_blank" rel="noreferrer noopener">Microsoft&#8217;s Blockbuster Quarter Cements Goldman&#8217;s Bullish AI, Cloud Thesis</a></li>
</ul>
Image: Shutterstock

Equities

Markets

What's Going On With Wayfair Stock On Thursday?

Acquisition of Wynshop builds upon Instacart's retailer relationships, and creates opportunity to bring Instacart's full suite of enterprise solutions to Wynshop partners to help them grow their business
SAN FRANCISCO, May 1, 2025 /PRNewswire/ --&nbsp;Instacart (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CART#NASDAQ">CART</a>), the leading grocery technology company in North America, today announced its acquisition of Wynshop, a provider of e-commerce solutions for leading grocers and retailers, including Wakefern, Pattison, and more than a dozen more across North America and abroad. The acquisition of Wynshop builds upon Instacart's relationships with retail partners and reinforces Instacart's continued commitment to providing retailers with cutting-edge tools and technologies that help drive their business growth. By bringing together both organizations' expertise and deep retailer relationships, Instacart aims to strengthen its enterprise solutions and empower more retailers to enhance their online experiences and further engage their customers.

CART

Reported Earlier: Instacart Acquires Wynshop To Accelerate The Expansion Of Its Enterprise Technology Solutions; No Financial Terms Disclosed

NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) shares are trading higher Thursday following strong quarterly reports from Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) and Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>). The stock also took another leg higher following reports suggesting a potential easing <a href="https://www.benzinga.com/government/regulations/25/04/45113788/huaweis-new-ai-cluster-takes-on-nvidia-but-at-a-higher-cost-following-sanctions">of chip restrictions</a>.
What To Know: The U.S. is considering pulling back on Nvidia chip sales restrictions to the United Arab Emirates, Bloomberg <a href="https://www.bloomberg.com/news/articles/2025-05-01/us-weighs-easing-nvidia-chip-curbs-on-uae-as-trump-plans-visit?embedded-checkout=true">reported</a> Thursday.
People familiar with the matter said President Donald Trump could be preparing to announce a bilateral chip deal in a planned trip to the Gulf region. 
Although on official decision hasn&#8217;t been made, talks of a potential easing have reportedly been picking up momentum at the White House and the Commerce Department. 
Trump is scheduled to make a trip to the UAE on May 15 as part of a broader visit to the Middle East slated to begin on May 13. The report indicates that companies are currently slated to start complying with the AI diffusion rule, which caps AI chip exports on about 100 countries, beginning that same day. 
Nvidia shares popped on the report, nearly touching $115 per share in trading Thursday before pulling back. The stock was still up approximately 4% at the time of writing, buoyed by AI optimism following strong reports from Microsoft and Meta.
Microsoft shares were up about 8.5% at last check after the company beat analyst estimates for the third quarter, driven by strong Azure and cloud services growth, which increased 33% year-over-year in the quarter.
Microsoft CEO Satya Nadella said AI and Cloud are &#8220;essential inputs&#8221; for every business in the company&#8217;s earnings release. 
Check This Out: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45137383/microsoft-rallies-after-crushing-q3-earnings-goldman-sachs-lifts-target-to-480">Microsoft&#8217;s Blockbuster Quarter Cements Goldman&#8217;s Bullish AI, Cloud Thesis</a>
Meta also reported&nbsp;<a href="https://www.benzinga.com/news/earnings/25/04/45117948/meta-q1-earnings-eps-beat-revenue-up-16-ai-approaches-1-billion-monthly-actives-capital-expenditures-forecast-raised" target="_blank" rel="noreferrer noopener">strong quarterly results</a>&nbsp;after the bell on Wednesday and raised its full-year capital expenditures forecast, which helped boost several AI-related names, reinforcing confidence in AI spending growth. 
"This updated&nbsp;outlook&nbsp;reflects additional data center investments to support our artificial intelligence efforts as well as an increase in the expected cost of infrastructure hardware," the company said.
Nvidia is set to report&nbsp;<a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">first-quarter financial results</a>&nbsp;after the market close on May 28. Analysts are currently forecasting earnings of 88 cents per share and revenue of $43.07 billion, according to estimates from&nbsp;<a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
The U.S. government informed Nvidia in April that it will <a href="https://www.benzinga.com/news/global/25/04/44828742/nvidia-stock-is-tumbling-after-hours-heres-why" target="_blank" rel="noreferrer noopener">need a license</a> to export certain chips to China. The company said last month that it expected its first-quarter results to include up to $5.5 billion of charges associated with products held in inventory as a result of the restrictions.
NVDA Price Action:&nbsp;<a href="http://benzinga.com/quote/nvda" target="_blank" rel="noreferrer noopener">Nvidia shares</a>&nbsp;were up 4.04% at $113.32 at the time of publication Thursday, according to&nbsp;<a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/05/45127580/nvidia-ceo-jensen-huang-sounds-alarm-as-50-of-ai-researchers-are-chinese-urges-america-to-reskill-amid-infinite-game">Nvidia CEO Jensen Huang Sounds Alarm As 50% Of AI Researchers Are Chinese, Urges America To Reskill Amid &#8216;Infinite Game&#8217;</a></li>
</ul>
Photo: <a href="https://www.shutterstock.com/g/Hepha1st0s">epha1st0s</a>/Shutterstock.

MSFT

NVDA

Nvidia Stock Is Rallying Thursday: What's Driving The Action?

AirSculpt Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRS#NASDAQ">AIRS</a>) is set to give its latest quarterly earnings report on Friday, 2025-05-02. Here's what investors need to know before the announcement.
Analysts estimate that AirSculpt Technologies will report an earnings per share (EPS) of $-0.03. 
Anticipation surrounds AirSculpt Technologies's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Past Earnings Performance</h3>
During the last quarter, the company reported an EPS missed by $0.10, leading to a 0.0% drop in the share price on the subsequent day.
Here's a look at AirSculpt Technologies's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.02</td>
<td>-0.05</td>
<td>0.04</td>
<td>-0.02</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.08</td>
<td>-0.02</td>
<td>0.09</td>
<td>0.03</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-3.0%</td>
<td>21.0%</td>
<td>1.0%</td>
<td>-12.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746122823_0.png" alt="eps graph" />
<h3>Tracking AirSculpt Technologies's Stock Performance</h3>
Shares of AirSculpt Technologies were trading at $2.17 as of April 30. Over the last 52-week period, shares are down 59.65%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<h3>Insights Shared by Analysts on AirSculpt Technologies</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on AirSculpt Technologies.
AirSculpt Technologies has received a total of 1 ratings from analysts, with the consensus rating as Neutral. With an average one-year price target of $2.5, the consensus suggests a potential 15.21% upside.
<h3>Analyzing Analyst Ratings Among Peers</h3>
The analysis below examines the analyst ratings and average 1-year price targets of Biodesix, DocGo and Vivos Therapeutics, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for Biodesix, with an average 1-year price target of $2.5, suggesting a potential 15.21% upside.</li>
<li>Analysts currently favor an Buy trajectory for DocGo, with an average 1-year price target of $4.5, suggesting a potential 107.37% upside.</li>
<li>Analysts currently favor an Buy trajectory for Vivos Therapeutics, with an average 1-year price target of $6.2, suggesting a potential 185.71% upside.</li>
</ul>
<h3>Overview of Peer Analysis</h3>
In the peer analysis summary, key metrics for Biodesix, DocGo and Vivos Therapeutics are highlighted, providing an understanding of their respective standings within the industry and offering insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>AirSculpt Technologies</td>
<td>Neutral</td>
<td>-17.71%</td>
<td>$22.43M</td>
<td>-6.22%</td>
</tr>
<tr>
<td>Biodesix</td>
<td>Buy</td>
<td>39.28%</td>
<td>$16.09M</td>
<td>-33.86%</td>
</tr>
<tr>
<td>DocGo</td>
<td>Buy</td>
<td>-39.35%</td>
<td>$40.50M</td>
<td>-1.01%</td>
</tr>
<tr>
<td>Vivos Therapeutics</td>
<td>Buy</td>
<td>13.85%</td>
<td>$2.10M</td>
<td>-36.20%</td>
</tr>
</tbody>
</table>

Key Takeaway:
AirSculpt Technologies ranks at the bottom for Revenue Growth and Gross Profit, while it is in the middle for Return on Equity. Overall, the company's performance is mixed compared to its peers.
<h3>All You Need to Know About AirSculpt Technologies</h3>
AirSculpt Technologies Inc is a national provider of body contouring procedures delivering a premium consumer experience under its brand Elite Body Sculpture. Elite Body Sculpture, provides custom body contouring using the proprietary AirSculpt method that removes unwanted fat in a minimally invasive procedure. The company has one operating and reportable segment, direct medical procedure services.
<h3>AirSculpt Technologies: A Financial Overview</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: AirSculpt Technologies's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately -17.71%. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: AirSculpt Technologies's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -12.85% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -6.22%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -2.41%, the company showcases effective utilization of assets.
Debt Management: AirSculpt Technologies's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.32, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<a href="https://www.benzinga.com/quote/AIRS/earnings">To track all earnings releases for AirSculpt Technologies visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AIRS

Uncovering Potential: AirSculpt Technologies's Earnings Preview

Oshkosh Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OSK#NYSE">OSK</a>) posted weaker-than-expected earnings for the <a href="https://www.benzinga.com/quote/OSK/earnings">first quarter on Wednesday</a>.
The company posted adjusted earnings of $1.92 per share, missing market estimates of $2.05 per share. The company's quarterly sales came in at $2.31 billion versus expectations of $2.41 billion.
&#8220;We are pleased with our start to 2025, led by strong performance in our Vocational segment, double-digit margins in our Access segment and solid progress on the ramp-up of Next Generation Delivery Vehicle production. Adjusted earnings per share of $1.92 was in line with our expectations of approximately $2.00 per share,&#8221; said John Pfeifer, president and chief executive officer of Oshkosh Corporation. &#8220;These results reflect the strength of our team and our People First culture, our portfolio of industry-leading businesses and the resilience of our operating model.
Oshkosh shares gained 3.8% to trade at $86.96 on Thursday.
These analysts made changes to their price targets on Oshkosh following earnings announcement.
<ul>
<li>Baird analyst Mircea Dobre maintained Oshkosh with an Outperform rating and lowered the price target from $163 to $135.</li>
<li>Truist Securities analyst Jamie Cook maintained the stock with a Hold and cut the price target from $94 to $93.</li>
<li>JP Morgan analyst Tami Zakaria maintained Oshkosh with a Neutral and lowered the price target from $100 to $92.</li>
</ul>
Considering buying OSK stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="582" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/01140424/image-13-1024x582.png" alt="" class="wp-image-897616" style="width:586px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/01140424/image-13-1024x582.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/01140424/image-13-300x170.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/01140424/image-13-768x436.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/01140424/image-13.png 1093w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/05/45135511/how-to-earn-500-a-month-from-apple-stock-ahead-of-q2-earnings">How To Earn $500 A Month From Apple Stock Ahead Of Q2 Earnings</a> </li>
</ul>
Photo via Shuterstock

These Analysts Slash Their Forecasts On Oshkosh Following Weak Q1 Results

Vince Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VNCE#NYSE">VNCE</a>) is gearing up to announce its quarterly earnings on Friday, 2025-05-02. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Vince Holding will report an earnings per share (EPS) of $-0.09.
Investors in Vince Holding are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Past Earnings Performance</h3>
The company's EPS beat by $0.02 in the last quarter, leading to a 0.0% drop in the share price on the following day.

<img src="https://www.benzinga.com/files/images/story/2025/1746122775_0.png" alt="eps graph" />
<h3>Tracking Vince Holding's Stock Performance</h3>
Shares of Vince Holding were trading at $1.71 as of April 30. Over the last 52-week period, shares are up 15.79%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analysts' Perspectives on Vince Holding</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Vince Holding.
Vince Holding has received a total of 5 ratings from analysts, with the consensus rating as Buy. With an average one-year price target of $5.6, the consensus suggests a potential 227.49% upside.
<h3>Analyzing Ratings Among Peers</h3>
The following analysis focuses on the analyst ratings and average 1-year price targets of Vera Bradley, Lakeland Industries and Superior Gr of Cos, three prominent industry players, providing insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for Vera Bradley, with an average 1-year price target of $4.6, suggesting a potential 169.01% upside.</li>
<li>Analysts currently favor an Buy trajectory for Lakeland Industries, with an average 1-year price target of $27.0, suggesting a potential 1478.95% upside.</li>
<li>Analysts currently favor an Buy trajectory for Superior Gr of Cos, with an average 1-year price target of $19.0, suggesting a potential 1011.11% upside.</li>
</ul>
<h3>Insights: Peer Analysis</h3>
The peer analysis summary presents essential metrics for Vera Bradley, Lakeland Industries and Superior Gr of Cos, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vince Holding</td>
<td>Buy</td>
<td>-4.66%</td>
<td>$40.06M</td>
<td>7.94%</td>
</tr>
<tr>
<td>Vera Bradley</td>
<td>Buy</td>
<td>-24.99%</td>
<td>$44.96M</td>
<td>-23.25%</td>
</tr>
<tr>
<td>Lakeland Industries</td>
<td>Buy</td>
<td>49.26%</td>
<td>$18.69M</td>
<td>-13.59%</td>
</tr>
<tr>
<td>Superior Gr of Cos</td>
<td>Buy</td>
<td>-1.24%</td>
<td>$53.96M</td>
<td>1.05%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Vince Holding ranks at the bottom for Revenue Growth among its peers. It is also at the bottom for Gross Profit. However, it is at the top for Return on Equity.
<h3>Discovering Vince Holding: A Closer Look</h3>
Vince Holding Corp is a fashion brand that is engaged in wholesale and retail delivery of luxury essentials like women's and men's apparel, women's and men's footwear, and handbags. Its offers women's collections of luxurious cashmere sweaters and silk blouses, leather and suede leggings and jackets, dresses, denim, pants, tanks and t-shirts, and a growing assortment of outerwear. It focuses on developing an elevated collection of Vince apparel and accessories to serve the luxurious need of the customer. The company manages its business in three segments namely Vince Wholesale, Vince Direct-to-consumer, and Rebecca Taylor and Parker segment. It operates its e-commerce business through its website. Majority of its revenue generated from Vince Wholesale segment.
<h3>A Deep Dive into Vince Holding's Financials</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3 months period, Vince Holding faced challenges, resulting in a decline of approximately -4.66% in revenue growth as of 31 October, 2024. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Discretionary sector.
Net Margin: Vince Holding's net margin excels beyond industry benchmarks, reaching 5.43%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Vince Holding's ROE stands out, surpassing industry averages. With an impressive ROE of 7.94%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.71%, the company showcases effective utilization of assets.
Debt Management: Vince Holding's debt-to-equity ratio surpasses industry norms, standing at 2.63. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<a href="https://www.benzinga.com/quote/VNCE/earnings">To track all earnings releases for Vince Holding visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

VNCE

Uncovering Potential: Vince Holding's Earnings Preview

JP Morgan analyst Brian Ossenbeck maintains XPO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPO#NYSE">XPO</a>) with a Overweight and lowers the price target from $132 to $121.

JP Morgan Maintains Overweight on XPO, Lowers Price Target to $121

Fulgent Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLGT#NASDAQ">FLGT</a>) is preparing to release its quarterly earnings on Friday, 2025-05-02. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Fulgent Genetics to report an earnings per share (EPS) of $-0.13.
The announcement from Fulgent Genetics is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Performance in Previous Earnings</h3>
The company's EPS beat by $0.16 in the last quarter, leading to a 0.0% drop in the share price on the following day.

<img src="https://www.benzinga.com/files/images/story/2025/1746122623_0.png" alt="eps graph" />
<h3>Market Performance of Fulgent Genetics's Stock</h3>
Shares of Fulgent Genetics were trading at $17.35 as of April 30. Over the last 52-week period, shares are down 19.86%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<h3>Analyst Views on Fulgent Genetics</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Fulgent Genetics.
A total of 1 analyst ratings have been received for Fulgent Genetics, with the consensus rating being Neutral. The average one-year price target stands at $16.0, suggesting a potential 7.78% downside.
<h3>Comparing Ratings Among Industry Peers</h3>
In this analysis, we delve into the analyst ratings and average 1-year price targets of Talkspace, Castle Biosciences and Nutex Health, three key industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for Talkspace, with an average 1-year price target of $5.0, suggesting a potential 71.18% downside.</li>
<li>Analysts currently favor an Outperform trajectory for Castle Biosciences, with an average 1-year price target of $37.0, suggesting a potential 113.26% upside.</li>
<li>Analysts currently favor an Buy trajectory for Nutex Health, with an average 1-year price target of $87.5, suggesting a potential 404.32% upside.</li>
</ul>
<h3>Overview of Peer Analysis</h3>
The peer analysis summary offers a detailed examination of key metrics for Talkspace, Castle Biosciences and Nutex Health, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fulgent Genetics</td>
<td>Neutral</td>
<td>8.10%</td>
<td>$31.85M</td>
<td>-0.52%</td>
</tr>
<tr>
<td>Talkspace</td>
<td>Buy</td>
<td>14.86%</td>
<td>$21.53M</td>
<td>1.03%</td>
</tr>
<tr>
<td>Castle Biosciences</td>
<td>Outperform</td>
<td>30.54%</td>
<td>$70.13M</td>
<td>2.14%</td>
</tr>
<tr>
<td>Nutex Health</td>
<td>Buy</td>
<td>269.77%</td>
<td>$141.63M</td>
<td>59.67%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Fulgent Genetics ranks at the bottom for Revenue Growth and Gross Profit, while it is in the middle for Return on Equity. The company's performance is below average compared to its peers in terms of revenue growth and gross profit, but it is relatively better in terms of return on equity.
<h3>About Fulgent Genetics</h3>
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.
<h3>A Deep Dive into Fulgent Genetics's Financials</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Fulgent Genetics's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 8.1%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -7.73%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Fulgent Genetics's ROE excels beyond industry benchmarks, reaching -0.52%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Fulgent Genetics's ROA excels beyond industry benchmarks, reaching -0.48%. This signifies efficient management of assets and strong financial health.
Debt Management: Fulgent Genetics's debt-to-equity ratio is below the industry average. With a ratio of 0.01, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<a href="https://www.benzinga.com/quote/FLGT/earnings">To track all earnings releases for Fulgent Genetics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FLGT

A Peek at Fulgent Genetics's Future Earnings

JP Morgan analyst Jessica Fye maintains United Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) with a Overweight and lowers the price target from $355 to $350.

UTHR

JP Morgan Maintains Overweight on United Therapeutics, Lowers Price Target to $350

USA Natural Gas Storage 107B Vs 109B Est.; 88B Prior

SES AI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SES#NYSE">SES</a>) will release its quarterly earnings report on Thursday, 2025-04-24. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate SES AI to report an earnings per share (EPS) of $-0.06.
Investors in SES AI are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Past Earnings Performance</h3>
In the previous earnings release, the company missed EPS by $0.02, leading to a 5.12% drop in the share price the following trading session.
Here's a look at SES AI's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.06</td>
<td>-0.09</td>
<td>-0.12</td>
<td>-0.08</td>
<td>-0.05</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.04</td>
<td>-0.11</td>
<td>-0.09</td>
<td>-0.06</td>
<td>-0.05</td>
</tr>
<tr>
<td>Price Change %</td>
<td>19.0%</td>
<td>-5.0%</td>
<td>-5.0%</td>
<td>-9.0%</td>
<td>-5.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746122580_0.png" alt="eps graph" />
<h3>SES AI Share Price Analysis</h3>
Shares of SES AI were trading at $0.8988 as of April 30. Over the last 52-week period, shares are down 34.42%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/SES/earnings">To track all earnings releases for SES AI visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Uncovering Potential: SES AI's Earnings Preview

Press Releases

NYLI CBRE Global Infrastructure Megatrends Term Fund (NYSE: MEGI) Declares Monthly Distribution for February 2025 and Availability of 19(a) Notice

CBRE Group, Inc. to Present at Morgan Stanley 2025 Commercial Real Estate Conference

NYLI CBRE Global Infrastructure Megatrends Term Fund (NYSE: MEGI) Declares Monthly Distributions for March, April and May 2025 and Availability of 19(a) Notice

CBRE Group, Inc. Announces Details of Conference Call and Webcast for First Quarter 2025 Financial Results

CBRE Group, Inc. Provides Recast Historical Financial Information for 2025 Business Segments

Real Estate

Shorenstein Commences Renovations at 14th & Spring in Atlanta

CBRE Global Real Estate Income Fund (NYSE: IGR) Declares Monthly Distributions for April, May and June and Announces a Webinar with Portfolio Management

NYLI CBRE Global Infrastructure Megatrends Term Fund (NYSE: MEGI) Declares Availability of Section 19(a) Notice for April 2025

CBRE Group, Inc. Reports Financial Results for First-Quarter 2025

CBRE Group, Inc. Announces Pricing of $600 Million Senior Notes Due 2030 and $500 Million Senior Notes Due 2035

CBRE

MEGI

Altisource Portfolio Solutions S.A. - Common Stock

Altisource Portfolio

KE Holdings Inc American Depositary Shares (each representing three Class A Ordinary Shares)

Comments

CBRE Group

空売り

CBRE Group (NYSE:CBRE) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル